Biotechnology Startups in Maryland

Capsulomics, Inc., now known as Previse, is a pioneering medical diagnostics company dedicated to the early detection and prevention of esophageal cancer. The firm leverages cutting-edge molecular testing to empower gastroenterologists with critical insights into patient risk profiles for more informed treatment options.

Elixirgen Therapeutics, Inc. is a cutting-edge biotechnology firm dedicated to the development of innovative RNA therapeutics aimed at addressing a broad spectrum of medical challenges. The company is committed to providing treatment solutions for rare diseases, cancer, and aging-related conditions that currently have limited therapeutic options.

Gliknik Inc. is a pioneering biopharmaceutical company that specializes in the development of innovative biologics aimed at treating cancer and autoimmune disorders. The company's unique approach to drug development sets it apart in the biotech industry, as it seeks to create more effective and accessible alternatives to existing treatments.

Infinity Bio, Inc. is an innovative biotechnology company focused on providing advanced antibody profiling services. Established in 2023 and headquartered in Baltimore, Maryland, the company utilizes cutting-edge technology developed at Johns Hopkins University to address the complexities of antibody responses within the immune system.

Founded 2023

Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing and discovering next-generation cancer therapeutics. The company utilizes its proprietary biologics platform to create treatments that selectively target the tumor microenvironment. Its primary goal is to advance its pipeline candidates through clinical trials and eventually commercialize them to treat various forms of cancer.

Zero Point Five Therapeutics, Inc., also known as ZP5 Therapeutics, is a biotechnology company focused on developing effective treatments for neglected tropical diseases, particularly soil-transmitted helminthiasis (STH). The company aims to create accessible therapies for diseases that disproportionately affect marginalized communities worldwide, addressing a critical health crisis caused by intestinal parasitic infections.